

Appendix Table F39. Quality of life after duloxetine vs. placebo

Reference sample size	Dose	Outcome measure, MID	Randomized to active/control	Mean +/- standard deviation active	Mean +/- standard deviation control	Mean difference (95% CI)
Yalcin, 2006 ⁴⁰⁸ 858	80mg daily	Increase in total I-QOL score from baseline; 2 to 5	433/425	10.5+/-14.0	6.4+/-12.6	4.1 (2.3; 5.90)
Yalcin, 2006 ⁴⁰⁸ 858	80mg daily	Increase in avoidance/limiting domain of I-QOL score from baseline	433/425	10.8+/-10.8	7.2+/-13.9	3.6 (1.9; 5.30)
Yalcin, 2006 ⁴⁰⁸ 858	80mg daily	Increase in psychosocial domain of I-QOL score from baseline	433/425	9.4+/-14.8	4.9+/-12.9	4.5 (2.6; 6.40)
Yalcin, 2006 ⁴⁰⁸ 858	80mg daily	Increase in social embarrassment domain of I-QOL score from baseline	433/425	12.1+/-18.4	8.1+/-17.6	4.0 (1.6; 6.40)
Dmochowski, 2003 ²⁷⁹ 683	40mg twice daily	Increase in I-QOL score from baseline	344/339	11.1+/-14.8	6.8+/-13.8	4.3 (2.2; 6.40)
Dmochowski, 2003 ²⁷⁹ 683	40mg twice daily	Increase in I-QOL score from baseline for the avoidance/limiting behavior domain	344/339	11.1+/-15.8	7.1+/-14.8	4.0 (1.7; 6.30)
Dmochowski, 2003 ²⁷⁹ 683	40mg twice daily	Increase in I-QOL score from baseline for psychosocial domain	344/339	10.2+/-15.5	5.7+/-14.6	4.5 (2.2; 6.80)
Dmochowski, 2003 ²⁷⁹ 683	40mg twice daily	Increase in I-QOL score from baseline for social embarrassment domain	344/339	12.4+/-19.8	8.4+/-18.6	4.0 (1.1; 6.90)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	I-QOL Total score (0 worse to 100)	227/231	69.2+/-23.8	64.7+/-24.9	4.5 (0.0; 9.00)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	I-QOL Total score (0 worse to 100)	227/231	69.0+/-24.4	64.9+/-24.9	4.1 (-0.4; 8.60)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	avoidance/limiting behavior- I-QOL subscale	227/231	69.7+/-23.7	65.5+/-24.7	4.2 (-0.2; 8.60)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	psychosocial- I-QOL subscale	227/231	75.5+/-24.8	71.4+/-26.2	4.1 (-0.6; 8.80)
Millard, 2004 ³⁵⁰ 458	40mg twice daily	social embarrassment- I-QOL subscale	227/231	57.1+/-27.8	51.5+/-29.7	5.6 (0.3; 10.90)
Steers, 2007 ³⁸¹ 306	40-60mg twice daily	I-QOL	153/153	65.0+/-23.8	62.0+/-25.3	3.0 (-2.5; 8.50)

Appendix Table F39. Quality of life after duloxetine vs. placebo (continued)

Reference sample size	Dose	Outcome measure, MID	Randomized to active/control	Mean +/- standard deviation active	Mean +/- standard deviation control	Mean difference (95% CI)
Cardozo, 2004 ²⁵¹ 109	40mg twice daily for 4 weeks, 60 mg twice daily for 4 weeks	Avoidance and Limiting Behavior, I-QOL Subscales	55/54	10.1+/-20.8	2.0+/-11.1	8.1 (1.9; 14.30)
Cardozo, 2004 ²⁵¹ 109	40mg twice daily for 4 weeks, 60 mg twice daily for 4 weeks	Psychosocial Impacts, I-QOL Subscales	55/54	10.6+/-18.7	2.1+/-9.6	8.5 (2.9; 14.10)
Cardozo, 2004 ²⁵¹ 109	40mg twice daily for 4 weeks, 60 mg twice daily for 4 weeks	Social Embarrassment, I-QOL Subscales	55/54	11.5+/-22.6	3.6+/-12.6	7.9 (1.0; 14.80)
Cardozo, 2004 ²⁵¹ 109	40mg twice daily for 4 weeks, 60 mg twice daily for 4 weeks	I-QOL total score	55/54	10.6+/-19.1	2.4+/-9.4	8.2 (2.6; 13.80)
Lin, 2008 ³³⁹ 121	40mg twice daily	Mean change in I-QOL from baseline	60/61	13.6+/-0.0	13.3+/-0.0	0.3 (-4.8; 6.80)
Lin, 2008 ³³⁹ 121	40mg twice daily	change from baseline in I-QOL avoidance and limiting behavior	60/61	12.7+/-0.0	12.8+/-0.0	-0.1 (-5.3; 6.50)
Lin, 2008 ³³⁹ 121	40mg twice daily	change from baseline in I-QOL psychological impact subscale score	60/61	12.9+/-0.0	12.0+/-0.0	0.9 (-3.7; 7.90)
Lin, 2008 ³³⁹ 121	40mg twice daily	change from baseline in I-QOL social embarrassment subscale score	60/61	16.4+/-0.0	16.5+/-0.0	-0.1 (-7.4; 6.80)
Viktrup, 2007 ³¹³ 1913	40mg twice daily	I-QOL mean % change, for patient's age <50	958/955	9.1+/-13.5	0.0+/-0.0	5.1 (-22.3; 32.50)
Viktrup, 2007 ³¹³ 1913	40mg twice daily	I-QOL mean % change, for patient's age ≥51	958/955	9.3+/-15.4	0.0+/-0.0	6.4 (-20.8; 33.60)